Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex
- First Online:
- Cite this article as:
- Cnop, M., Havel, P.J., Utzschneider, K.M. et al. Diabetologia (2003) 46: 459. doi:10.1007/s00125-003-1074-z
- 3.9k Downloads
Increased intra-abdominal fat is associated with insulin resistance and an atherogenic lipoprotein profile. Circulating concentrations of adiponectin, an adipocyte-derived protein, are decreased with insulin resistance. We investigated the relationships between adiponectin and leptin, body fat distribution, insulin sensitivity and lipoproteins.
We measured plasma adiponectin, leptin and lipid concentrations, intra-abdominal and subcutaneous fat areas by CT scan, and insulin sensitivity index (SI) in 182 subjects (76 M/106F).
Adiponectin concentrations were higher in women than in men (7.4±2.9 vs 5.4±2.3 µg/ml, p<0.0001) as were leptin concentrations (19.1±13.7 vs 6.9±5.1 ng/ml, p<0.0001). Women were more insulin sensitive (SI: 6.8±3.9 vs 5.9±4.4×10−5 min−1/(pmol/l), p<0.01) and had more subcutaneous (240±133 vs 187±90 cm2, p<0.01), but less intra-abdominal fat (82±57 vs 124±68 cm2, p<0.0001). By simple regression, adiponectin was positively correlated with age (r=0.227, p<0.01) and SI (r=0.375, p<0.0001), and negatively correlated with BMI (r=−0.333, p<0.0001), subcutaneous (r=−0.168, p<0.05) and intra-abdominal fat (r=−0.35, p<0.0001). Adiponectin was negatively correlated with triglycerides (r=−0.281, p<0.001) and positively correlated with HDL cholesterol (r=0.605, p<0.0001) and Rf, a measure of LDL particle buoyancy (r=0.474, p<0.0001). By multiple regression analysis, adiponectin was related to age (p<0.0001), sex (p<0.005) and intra-abdominal fat (p<0.01). SI was related to intra-abdominal fat (p<0.0001) and adiponectin (p<0.0005). Both intra-abdominal fat and adiponectin contributed independently to triglycerides, HDL cholesterol and Rf.
These data suggest that adiponectin concentrations are determined by intra-abdominal fat mass, with additional independent effects of age and sex. Adiponectin could link intra-abdominal fat with insulin resistance and an atherogenic lipoprotein profile.
KeywordsAdiponectin Acrp30 adipoQ central obesity subcutaneous fat intra-abdominal fat insulin sensitivity lipids hepatic lipase cardiovascular disease leptin
insulin sensitivity index
density gradient ultracentrifugation
tumor necrosis factor-α
It is well recognized that obesity and insulin resistance are closely related [1, 2, 3, 4]. Android body fat distribution is associated with insulin resistance more than is a gynoid body fat distribution , with the site of abdominal fat distribution being an additional determinant of insulin sensitivity [6, 7, 8, 9, 10, 11]. We found in both lean and obese subjects that the intra-abdominal fat (IAF) depot is a stronger determinant of insulin sensitivity than the subcutaneous fat (SCF) depot , while SCF is the main determinant of the plasma concentration of leptin , an adipocyte-derived hormone regulating energy metabolism [12, 13].
There is great interest in the relationship between body fat distribution and insulin sensitivity due to their role in cardiovascular disease and Type 2 diabetes, but the mediators of this interaction between body fat and insulin sensitivity remain uncertain. A role has been suggested for NEFA as they are commonly increased in states associated with insulin resistance [14, 15, 16] and induce insulin resistance in vivo and in vitro [15, 16]. The lipolytically more active intra-abdominal fat  is an important source of NEFA in the portal circulation, draining them directly to the liver and thereby altering hepatic glucose and lipid metabolism [18, 19, 20]. Recently, it has been shown in mice fed a high fat, high sucrose diet that administration of the recently characterized adipocyte secreted protein adiponectin increases fat oxidation, thereby reducing NEFA concentrations and body weight .
Adiponectin, also known as apM1 , Acrp30 , GBP28  or adipoQ , has been suggested to be an important regulator of insulin action, thereby possibly linking adiposity and insulin sensitivity [26, 27]. Unlike many of the other "adipokines" such as tumour necrosis factor-α (TNF-α), leptin and resistin that increase with adiposity , circulating adiponectin concentrations are reduced in individuals who are obese [28, 29, 30, 31], have cardiovascular disease  or Type 2 diabetes . Circulating adiponectin concentrations are correlated with insulin sensitivity [30, 31], with low concentrations predicting a future decrease in insulin sensitivity in Pima Indians . Furthermore, low adiponectin concentrations have been associated with a more atherogenic lipid profile  and have been shown to increase with thiazolidinedione administration [35, 36]. Studies in animals also suggest that adiponectin could be an important determinant of insulin action. Thus, a decline in adiponectin concentrations has been shown to coincide with the development of hyperinsulinaemia and insulin resistance in obese rhesus monkeys  while both heterozygous and homozygous adiponectin null mice have a phenotype of insulin resistance with a gene dose effect  and develop marked diet-induced insulin resistance .
Based on these observations, we hypothesized that central adiposity and specifically visceral adiposity is an important determinant of adiponectin and could be important in linking adiposity to insulin sensitivity. Therefore, we examined the relationships of adiponectin concentrations with insulin sensitivity, body fat distribution and lipids in a large cohort of apparently healthy human subjects in whom we have rigorously quantified these parameters. The questions we posed were the following: (i) Are adiponectin concentrations related to body fat distribution and if so, is one abdominal fat depot more strongly related to adiponectin than another? (ii) Are adiponectin concentrations related to an atherogenic lipid profile and if so, to which lipoprotein measure? (iii) Do age and sex have an impact on these relationships?
Subjects and Methods
We recruited 182 individuals (76 men/106 women) aged 32 to 75 years by advertisement, from the Greater Seattle area, to participate in a study on the effect of insulin sensitivity on the lipoprotein profile response to egg consumption . Eligible subjects had to be apparently healthy with no known history of diabetes, coronary artery disease or other vascular disease. In addition, they could not be receiving treatment for lipid disorders or hypertension and had to be free of renal or hepatic disease. At the time of screening, qualifying individuals had to have a fasting plasma glucose less than 6.4 mmol/l, LDL cholesterol less than 4.9 mmol/l and triglycerides less than 5.7 mmol/l. The study was reviewed and approved by the Human Subjects Review Committee at the University of Washington and written informed consent was obtained from all subjects. All data shown in this analysis are baseline measurements carried out at the start of the study.
Characterization of body size and fat distribution
Body mass index (BMI) was calculated as weight (kg)/[height (m)]2. The waist-to-hip ratio was calculated as waist circumference (cm)/hip circumference (cm) .
A computed tomography (CT) scan at the level of the umbilicus was used to quantify SCF and IAF areas . For this purpose, the border of the intra-abdominal cavity was outlined on the CT image and total fat and IAF areas were quantified by selecting an attenuation range of –250 to −50 Hounsfield units. SCF area was calculated as the difference between total fat area and IAF area. The variability of these measures made by a single observer is 1.5% and day to day variability is less than 1% .
Insulin sensitivity was quantified as the insulin sensitivity index (SI) using Bergman's minimal model of glucose kinetics . For this purpose, the glucose and insulin data obtained during a frequently sampled intravenous glucose tolerance test modified by the injection of tolbutamide were analyzed [45, 46]. The day to day variability of SI in our laboratory is 16.9% .
All analyses were carried out on blood samples drawn after an overnight fast of at least 12 h and were stored at −70°C until assayed. All samples were then measured in duplicate in each assay. Plasma glucose concentrations were measured using the glucose oxidase method. Immunoreactive insulin concentrations were measured in plasma by radioimmunoassay using a modification of a double antibody method . Plasma leptin concentrations were also measured by radioimmunoassay (Linco Research, St. Louis Mo., USA) .
Plasma adiponectin concentrations were measured using a radioimmunoassay for human adiponectin (Linco Research). The assay utilizes 125I-labelled adiponectin and an anti-adiponectin rabbit antiserum to measure adiponectin concentrations by the double antibody/PEG technique. Standards over the range of 1 to 200 ng/ml were prepared using recombinant human adiponectin. All plasma samples were diluted 1:200 yielding an effective range of 0.2 to 40 µg/ml. The intra-assay and inter-assay coefficients of variation at adiponectin concentrations in the range of 3 to 15 µg/ml are 1.8 to 6.2% and 6.9 to 9.3%, respectively. Plasma adiponectin concentrations measured in 40 paired samples using this assay and ELISA  were similar (10.4±6.6 vs 10.1±5.5 µg/ml) and linearly related (r=0.896, p<0.0001; M.K. Sinha, unpublished observation).
Plasma triglycerides and total cholesterol were measured by enzymatic analytical chemistry. HDL cholesterol was precipitated using dextran-sulphate and measured enzymatically. The LDL cholesterol concentration was calculated using the Friedewald equation: LDL cholesterol=total cholesterol−HDL cholesterol−(triglycerides/5). Apolipoprotein B (apoB) was measured by nephelometry  and non-equilibrium density gradient ultracentrifugation (DGUC) was carried out with the collection of 38 fractions in which cholesterol was measured . The LDL relative flotation index (Rf), a measure of LDL particle buoyancy, was measured by dividing the fraction number containing the highest LDL cholesterol concentration by 38, the latter representing the total number of fractions sampled. Lipoprotein measures were carried out in only 170 subjects with Rf not being measured in an additional eight individuals.
Data are expressed as means ± SD. Normality of distribution of the data was tested by the Kolmogorov-Smirnov test, a p value greater than 0.05 indicated that the observed distribution of a variable is not statistically different from the normal distribution. Comparison of demographic and metabolic variables by sex was done by unpaired t test and by Mann-Whitney U test when the data were not normally distributed. The relative contribution of age, sex and abdominal fat compartments was examined by analyses of subgroups of men and women and of young and older subjects. These subject groups were matched for IAF by pairwise selection of individuals with IAF differing by less than or equal to 10 cm2 and were then compared by unpaired t tests or Mann-Whitney U tests.
Scatterplots were used to visually evaluate the relationships between continuous variables in the whole cohort of 182 subjects and when subdivided by sex. Correlations were done by linear regression. Multiple regression analysis was used to determine whether the association between the dependent and independent variables of interest remained significant after adjusting for other potentially confounding independent variables. For this analysis, the dependent variables were natural log (loge) transformed if they were not normally distributed to satisfy the necessary statistical assumptions of linear regression. Stepwise model building was used to estimate the relative contribution of the independent variables and the variability of the dependent variable. Data with a p value less than or equal to 0.05 were considered statistically significant.
Demographic and phenotypic characteristics
Age, body fat distribution, metabolic characteristics and lipoprotein measurements
SCF area (cm2)
IAF area (cm2)
SI [×10−5 min−1/(pmol/l)]
HDL cholesterol (mmol/l)
LDL cholesterol (mmol/l)
Apolipoprotein B (mmol/l)
Men and women were well matched for age and BMI but differed in their distribution of body fat. Men had a greater waist-to-hip ratio and more IAF but less SCF. In addition, in men insulin sensitivity was lower, glucose was higher, and both leptin and adiponectin concentrations were lower. HDL cholesterol and the relative flotation index (Rf), a measure of LDL particle buoyancy, were also lower in men (Table 1).
Relationship of adiponectin concentrations with insulin sensitivity
Relationship of adiponectin concentrations with body fat distribution and plasma leptin concentrations
Simple regression analysis was used to initially examine the relationship between adiponectin concentrations and body fat distribution. The relationships between adiponectin concentrations and BMI, waist-to-hip ratio, and SCF and IAF areas were inverse (Fig. 2A–D). The highest correlation coefficient was observed for the relationship of waist-to-hip ratio with adiponectin (r=−0.360, p<0.0001) followed by IAF (r=−0.350, p<0.0001), BMI (r=−0.333, p<0.0001), and SCF (r=−0.168, p<0.05). The correlation between waist-to-hip ratio and adiponectin concentrations was largely the result of the sex-based difference in this measure of body fat distribution (Fig. 2G).
As adiponectin and leptin are both adipocyte-derived proteins, we also examined the relationship between them (Fig. 2E). Despite the fact that they are both derived from adipocytes, we did not observe a correlation between these two parameters in the whole cohort (r=−0.05), although there was a negative correlation when the subjects were subdivided by sex (men: r=−0.239, p<0.05; women: r=−0.278, p<0.01; Fig. 2J).
Relationship of sex and age to adiponectin concentrations
Simple regression analyses examining the sex-based relationship between plasma adiponectin concentrations and insulin sensitivity (Fig. 1B) and body fat distribution (Fig. 2F–I) were also carried out. The slopes of the regression lines were similar, but it is apparent that women have higher adiponectin concentrations than men for similar values for each of the independent variables. The distribution plots of adiponectin concentrations (Fig. 4B, C) also illustrate that concentrations are higher in women than in men.
Body fat distribution and fasting plasma adiponectin concentrations in a subgroup of men and women matched for age and IAF area
SCF area (cm2)
IAF area (cm2)
SI [×10−5 min−1/(pmol/l)]
To assess the relationship between age and adiponectin concentrations, we carried out simple linear regression. Interestingly, while aging is associated with an increase in IAF and a decrease in insulin sensitivity we observed an increase in adiponectin concentrations (r=0.227, p<0.01; Fig. 3A), which existed in both sexes (men: r=0.333, p<0.01; women: r=0.201, p<0.05; Fig. 3B).
Adiponectin concentrations, body fat distribution and metabolic characteristics of subjects, subdivided by age
SCF area (cm2)
IAF area (cm2)
SI [×10−5 min−1/(pmol/l)]
Multiple linear regression analysis of the relationship between adiponectin concentrations and age, sex and measures of body fat distribution
Relationship of insulin sensitivity with body fat distribution and adiponectin concentrations
Multiple linear regression analysis of the relationship between SI and age, sex, measures of body fat distribution and adiponectin concentrations
Relationship of plasma lipoproteins to adiponectin concentrations
Multiple linear regression analysis of the relationship between lipoprotein concentrations and age, gender, measures of body fat distribution, insulin sensitivity and adiponectin
Adiponectin has been postulated to be an important mediator of the interaction between adiposity and insulin sensitivity. In this large cohort of apparently healthy subjects, we examined the relationships between plasma adiponectin concentrations, insulin sensitivity, body fat distribution and plasma lipoproteins and the impact of age and sex. While our study is cross-sectional and therefore does not establish cause and effect relationships, we observed a number of interesting associations. We found that plasma adiponectin concentrations are positively correlated with insulin sensitivity while body size and intra-abdominal fat distribution are negatively related to its circulating concentrations. Further, adiponectin concentrations correlate strongly with the concentration of HDL cholesterol and LDL particle size.
It has previously been reported that insulin sensitivity based on a clamp measurement and adiponectin are related, although for analysis purposes both these variables were log transformed because their distribution was not normal . In this study we have not carried out such a transformation as adiponectin concentrations were normally distributed, perhaps because our population had broad ranges of age and body anthropometry. Our finding of a positive relationship between adiponectin and insulin sensitivity supports the notion that adiponectin concentrations could modulate insulin action. This finding is supported by studies in heterozygous and homozygous adiponectin null mice which showed a dose-dependent effect of adiponectin deficiency on insulin sensitivity . Further, administration of adiponectin reduced insulin resistance in mice that are genetically predisposed to obesity and diabetes by enhancing fatty acid oxidation resulting in reduced circulating NEFA concentrations and tissue triglyceride content  and by augmenting insulin's ability to suppress hepatic glucose production [52, 53].
The finding of an inverse relationship between BMI and adiponectin concentrations is in keeping with previous reports in Japanese subjects , Pima Indians and Caucasians . We have now found that central obesity and intra-abdominal fat accumulation are associated with declining adiponectin concentrations. The nature of this relationship was similar in men and women. These findings are in keeping with the recent observation that cultured adipocytes derived from the intra-abdominal fat depot secrete adiponectin more actively than subcutaneous fat derived adipocytes .
Our observations regarding the impact of sex suggest that adiponectin production is also related to factors independent of body fat distribution. At any particular body size or body fat distribution, adiponectin concentrations are greater in women than in men. Further, in men and women pair-matched for age, BMI, IAF and insulin sensitivity, adiponectin concentrations were greater in women. In addition, in a multiple linear regression analysis that included body size and body fat distribution, sex again had an independent effect on adiponectin concentrations. This finding of a sex-based difference in plasma adiponectin concentrations is supported by some [28, 31, 55] but not all [30, 56] other studies. However, the current findings are the first to account for the known sex-based differences in body fat distributions and strongly support the concept that sex has an additional independent effect to modulate adiponectin concentrations. The number of fat cells and fat cell size, both of which vary between sexes, are possible determinants of adiponectin production rates. Furthermore, it was recently reported that androgens decrease plasma adiponectin concentrations in vivo as well as adiponectin secretion from 3T3-L1 adipocytes in vitro .
In this cohort of subjects with a broad age range, we observed increasing adiponectin concentrations with increasing age. Normal aging is associated with the development of insulin resistance [57, 58] and increased fat accumulation in the central and predominantly in the intra-abdominal depot [59, 60]. These changes would be predicted to be associated with a decline in adiponectin concentrations with age, yet we observed the opposite. Sex steroids could be responsible for some of these changes as both testosterone  and estrogen have been shown to inhibit adiponectin production  and they both decline with age. A reduction in adiponectin clearance in older individuals is another possible contributor to the age-related increase in adiponectin. However, at this time, no information is available regarding the mechanism(s) of adiponectin clearance in humans or animals. Alternatively, our findings could also be explained by the selection of subjects in our study. If low adiponectin concentrations are predictive of the development of diabetes [37, 62], it is conceivable that older subjects with low adiponectin concentrations were excluded from our study because they were hyperglycaemic.
It is well recognized that dyslipidaemia is associated with central obesity and insulin resistance . In this study we found that both IAF and adiponectin were major correlates of plasma lipoproteins, in particular of LDL buoyancy (Rf) and HDL cholesterol concentrations, in keeping with other reports [31, 34, 64]. These relationships could be mediated by effects of adiponectin on hepatic lipase activity, which is increased in central obesity and insulin resistance states associated with the metabolic syndrome [65, 66]. While hepatic lipase does not seem to be acutely regulated by insulin , it could be increased by reduced adiponectin concentrations. The adverse lipoprotein profile is likely to be only one aspect of the cardiovascular risk associated with low adiponectin concentrations in humans. In mice, the deletion of the adiponectin gene is associated with insulin resistance and neointimal hyperplasia . Further, in vitro adiponectin inhibits monocyte adhesion to endothelial cells likely by reducing the TNF-α mediated inflammatory response  and decreasing macrophage to foam cell transformation . Thus, it is possible that decreased adiponectin concentrations play a critical role in the pathogenesis of atherosclerosis via various mechanisms.
IAF is a major source of adiponectin and NEFA (Fig. 6B). An increase in this fat depot will decrease adiponectin and increase NEFA, which in turn will result in an antagonism of insulin's effects in liver and peripheral tissues, primarily muscle. As adiponectin enhances insulin's effect to suppress hepatic glucose production, reduced adiponectin will decrease the effect of insulin to inhibit hepatic glucose production. In addition, we hypothesize that with low adiponectin concentrations and resultant hepatic insulin resistance, hepatic lipase activity will increase leading to a reduction in HDL cholesterol and a decrease in LDL buoyancy, two critical features of the metabolic syndrome and increased atherogenic risk. This hepatic insulin resistance and increased plasma NEFA concentrations will shift the fate of apolipoprotein B away from degradation towards secretion by the liver, resulting in increased triglyceride concentrations . Finally, a reduction in adiponectin concentrations would be anticipated to impair insulin action in the peripheral tissues resulting in less efficient glucose uptake and the deposition of triglyceride in the muscle .
In summary, we have examined the relationship between adiponectin and body fat distribution in apparently healthy subjects and have found evidence to suggest that plasma adiponectin is more closely related to IAF than SCF and that it could be an intermediate in the relationship between visceral obesity and insulin resistance. Further, from these cross-sectional data we have found evidence that age and sex may have effects independent of IAF to determine adiponectin production. Finally, the relationship between adiponectin and plasma lipoproteins suggests that a reduction in adiponectin concentrations is associated with decreased HDL cholesterol and small dense LDL particles, an event likely mediated via an increase in hepatic lipase activity.
We wish to thank the participants in this study without whose contribution these analyses would not have been possible. We wish to acknowledge the nursing efforts of D. Collins and the staff of the General Clinical Research Centre at the University of Washington and the data management effort of B. Fish. Dr. S. Marcovina and the staff of the Northwest Lipid Research Laboratory and the Immunoassay Core of the Diabetes Endocrinology Research Centre are acknowledged for the performance of glucose, insulin and lipoprotein measurements and K. Stanhope and J. Graham for the leptin and adiponectin assays. This work was supported in part by the Medical Research Service of the Department of Veterans Affairs, the American Egg Board, NIH grants DK-02456, DK-02654, DK-17047, DK-35747, DK-35816, DK-59417, HL-30086 and RR-37, the American Diabetes Association, the U.S. Department of Agriculture, and the McMillen Family Trust. M.C. was supported by a fellowship from the Belgian American Educational Foundation.